KWCN-41

KWCN-41 is a selective and efficient inhibitor of RIPK1 kinase with an IC 50 value of 88 nM. KWCN-41 specifically inhibits cell necrosis but does not inhibit apoptosis . KWCN-41 also has anti-inflammatory effects In Vitro KWCN-41 (10, 50, 250 nM; 1 h) inhibits L929 cell necroptosis in a dosedependent manner and increases the number of cells in the viable cell zone. KWCN-41 (10, 50, 250 nM; 0.5, 1.5, 2.5 h) inhibits the phosphorylation of RIPK1/3 and MLKL in L929 cells. KWCN-41 (0-10 μM) inhibits TZ-induced necroptosis of L929 cells in a dose-dependent manner and similarly protects cells from TSZ (TNF-α, Smac mimetic, and z-VAD-FMK)-induced necroptosis of HT-29 and U937 cells. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability AssayCell Line: L929 cells Concentration: 10, 50, 250 nM Incubation Time: 1 h Result: Inhibited L929 cell necroptosis in a Dosedependent manner and increased the number of cells in the viable cell zone. In Vivo KWCN-41 (10, 25, 40 mg/kg; i.p.; 72 h) dose-dependently inhibits TNF-α-induced death and improves survival in mice . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Inflammatory mouse model Dosage: 10, 25, 40 mg/kg Administration: i.p.; dissolved in saline containing 10% DMSO and 20% Tween80; 72 h Result: At 25, 40 mg/kg completely inhibited TNF-α induced death in mice, achieving 100% survival compared to 75% survival at 10 mg/kg. Form:Solid IC50& Target:RIPK1 88 nM (IC 50 )

No numbering system information yet

No physical and chemical property information yet

No safety information yet

No production method and use information yet

No upstream information yet

No downstream information yet

No related product information yet